Dong-A ST said its partner Sanwa Kagaku Kenkyusho has requested approval to launch a biosimilar of Amgen and Kyowa Hakko Kirin's anaemia therapy Aranesp in Japan, The Korea Herald reported.
If approved, Dong-A ST will manufacture the therapy, named DA-3880, while Sanwa Kagaku Kenkyusho will be responsible for distribution.
"The Japanese biosimilar market is expected to increase significantly due to the growing needs for medical expense deduction as the country is inching closer toward a super-aged society," a Dong-A ST official commented.
Sales of Aranesp in Japan reached $439 million last year, with global revenue equalling $3 billion.
To read more NewsPoints articles, click here.